Clinical picture and prognosis of multiple sclerosis in the era of disease-modifying therapies in the city of Novosibirsk
https://doi.org/10.31549/2542-1174-2025-9-4-80-90
Abstract
Introduction. Multiple sclerosis (MS) is a major cause of disability among young people after traumatic injuries. Many studies indicate changes in the clinical picture of MS over time, which is partly attributed to the use of pathogenetic therapy.
Aim. To study the changes in the clinical picture of MS between 01.01.2003 and 31.12.2022 in Novosibirsk.
Materials and methods . 1783 patients with MS diagnosed in the period from 01.01.2003 to 31.12.2022, who lived in Novosibirsk, were included in the study. The clinical picture was described (symptoms grouped by functional systems of the Kurtzke Expanded Disability Status Scale (EDSS)); besides, the MS phenotype, EEDSS score, and whether MS disease-modifying therapies (MSDMTs) were prescribed indicating their duration, were determined. The number of symptoms at the onset (mono- and polysymptomatic) and the grade of recovery of neurological disorders were assessed. The achievement of EDSS 3,0 and EDSS 6,0 in the group of “controlled” MS was also analyzed, considering the following indices: duration of the disease (time from the onset of the clinical phase of MS to 12.31.2022), the interval “onset – EDSS 3,0”, the interval “onset – EDSS 6,0”. This group included 1494 patients who met two criteria: MSDMTs for at least 6 months, and the duration of the MS clinical phase for at least 2 years.
Results . Pathogenetic therapy of MS changed the course of the disease. The clinical picture of MS was characterized by an increase in the proportion of patients with a remitting course (from 52 to 75%, p < 0,05). The role of the gender of patients in achieving permanent disability has decreased. The onset symptoms were found to be of great importance in the long-term prognosis of persistent disability (p < 0,05).
Conclusion. Gender, age, symptoms at the MS onset, and the use of pathogenetic therapy correlate with the risk and likelihood of achieving permanent disability (p < 0,05).
Supporting agencies: The research was supported by a grant from the Russian Science Foundation (Project No. 23-15-00377).
About the Authors
I. E. Arkhipov
Novosibirsk State Medical University; State Novosibirsk Regional Clinical Hospital
Russian Federation
Russian Federation
Ivan E. Arkhipov – Post-graduate Student, Department of Neurology; Neurologist, Regional Center for Multiple Sclerosis and other Autoimmune Diseases of the Nervous System
52, Krasny prosp., Novosibirsk, 630091
A. I. Prokayeva
Novosibirsk State Medical University; State Novosibirsk Regional Clinical Hospital; International Tomographic Center
Russian Federation
Russian Federation
Anna I. Prokayeva – Post-graduate Student, Department of Neurology; Neurologist, Regional Center for Multiple Sclerosis and other Autoimmune Diseases of the Nervous System; Researcher
Novosibirsk
D. S. Korobko
Novosibirsk State Medical University; State Novosibirsk Regional Clinical Hospital; International Tomographic Center
Russian Federation
Russian Federation
Denis S. Korobko – Cand. Sci. (Med.), Assistant, Department of Neurology; Head, Regional Center for Multiple Sclerosis and other Autoimmune Diseases of the Nervous System; Senior Researcher
Novosibirsk
N. A. Malkova
Novosibirsk State Medical University; State Novosibirsk Regional Clinical Hospital; International Tomographic Center
Russian Federation
Russian Federation
Nadezhda A. Malkova – Dr. Sci. (Med.), Professor, Department of Neurology; Curator, Regional Center for Multiple Sclerosis and other Autoimmune Diseases of the Nervous System; Chief Researcher
Novosibirsk
References
1. Koch-Henriksen N., Thygesen L.C., Stenager E. et al. Incidence of MS has increased markedly over six decades in Denmark particularly with late onset and in women // Neurology. 2018;90(22):e1954-e1963. DOI: 10.1212/WNL.0000000000005612.
2. Gusev E.I., Boyko A.N. (2020). Multiple Sclerosis: A Scientifi c and Practical Guide in 2 Volumes. Moscow. Vol. 1. P. 391–479. (In Russ.)
3. Malkova N.A., Ierusalimskiy A.P. (2006). Multiple Sclerosis. Novosibirsk. P. 54–93. (In Russ.)
4. Filippi M., Amato M.P., Centonze D. et al. Early use of high-effi cacy disease modifying therapies makes the diff erence in people with multiple sclerosis: an expert opinion // J. Neurol. 2022;269(10):5382-5394. DOI: 10.1007/s00415-022-11193-w.
5. Simonsen C.S., Flemmen H.Ø., Broch L. et al. The course of multiple sclerosis rewritten: a Norwegian population-based study on disease demographics and progression // J. Neurol. 2021;268(4):1330-1341. DOI: 10.1007/s00415-020-10279-7.
6. Simonsen C.S., Flemmen H.Ø., Broch L. et al. Early high effi cacy treatment in multiple sclerosis is the best predictor of future disease activity over 1 and 2 years in a Norwegian population-based registry // Front. Neurol. 2021;12:693017. DOI: 10.3389/fneur.2021.693017.
7. Multiple sclerosis: clinical guidelines. (2022). URL: a0f94b14685f83883eb1b7e90bd8cd95.pdf (accessed 20.06.2025).
8. Correale J., Rush C.A., Barboza A. Are highly active and aggressive multiple sclerosis the same entity? // Front. Neurol. 2023;14:1132170. DOI: 10.3389/fneur.2023.1132170.
9. Iacobaeus E., Arrambide G., Amato M.P. et al.; 2018 ECTRIMS Focused Workshop Group. Aggressive multiple sclerosis (1): Towards a defi nition of the phenotype // Mult. Scler. 2020; 26(9):1352458520925369. DOI: 10.1177/1352458520925369.
10. Menon S., Shirani A., Zhao Y. et al. Characterising aggressive multiple sclerosis // J. Neurol. Neurosurg. Psychiatry. 2013;84(11):1192-1198. DOI: 10.1136/jnnp-2013-304951.
11. Mathey G., Pisché G., Soudant M. et al. Long-term analysis of patients with benign multiple sclerosis: new insights about the disability course // J. Neurol. 2021;268(10):3817-3825. DOI: 10.1007/s00415-021-10501-0.
12. Tallantyre E.C., Major P.C., Atherton M.J. et al. How common is truly benign MS in a UK population? // J. Neurol. Neurosurg. Psychiatry. 2019;90(5):522-528. DOI: 10.1136/jnnp-2018-318802.
13. McFaul D., Hakopian N.N., Smith J.B. et al. Defi ning benign/burnt-out MS and discontinuing di sease-modifying therapies // Neurol. Neuroimmunol. Neuroinfl amm. 2021;8(2):e960. DOI: 10.1212/NXI.0000000000000960.
14. Amato M.P., Fonderico M., Portaccio E. et al. Disease-modifying drugs can reduce disability progression in relapsing multiple sclerosis // Brain. 2020;143(10):3013-3024. DOI: 10.1093/brain/awaa251.
15. Chalmer T.A., Baggesen L.M., Nørgaard M. et al.; Danish Multiple Sclerosis Group. Early versus later treatment start in multiple sclerosis: a register-based cohort study // Eur. J. Neurol. 2018;25(10):1262-e110. DOI: 10.1111/ene.13692.
16. Kalincik T., Diouf I., Sharmin S. et al.; MSBase Study Group. Eff ect of disease-modifying therapy on disability in relapsing-remitting multiple sclerosis over 15 years // Neurology. 2021;96(5):e783-e797. DOI: 10.1212/WNL.0000000000011242.
17. McKay K.A., Hillert J., Manouchehrinia A. Long-term disability progression of pediatric-onset multiple sclerosis // Neurology. 2019;92(24):e2764-e2773. DOI: 10.1212/WNL.0000000000007647.
18. Lashсh N.Yu., Pavlicov A.E., Boyko A.N. The development of multiple sclerosis over the age of 50. S.S. Korsakov Journal of Neurology and Psychiatry. 2023;123(9):21-25. DOI: 10.17116/jnevro202312309121. (In Russ.)
19. Mouresan E.F., Mentesidou E., Berglund A. et al. Clinical characteristics and long-term outcomes of late-onset multiple sclerosis: a Swedish nationwide Study // Neurology. 2024; 102(6):e208051. DOI: 10.1212/WNL.0000000000208051.
20. Sıvacı A.Ö., Seferoğlu M., Piri Çınar B. et al. Clinical and demographic characteristics of late-onset multiple sclerosis: LOMS-TR study // Mult. Scler. Relat. Disord. 2024;84:105469. DOI: 10.1016/j.msard.2024.105469.
Review
For citations:
Arkhipov I.E., Prokayeva A.I., Korobko D.S., Malkova N.A. Clinical picture and prognosis of multiple sclerosis in the era of disease-modifying therapies in the city of Novosibirsk. Journal of Siberian Medical Sciences. 2025;(4):80-90. https://doi.org/10.31549/2542-1174-2025-9-4-80-90
Views:
10
Email this article 